Concomitant low-dose doxorubicin treatment and exercise

Area of Science:

• Cardiology
• Oncology
• Exercise Physiology

Background:

• Doxorubicin (DOX) is a potent chemotherapy agent with known cardiotoxicity.
• Cancer patients undergoing DOX treatment may experience adverse cardiac effects.
• The potential of exercise to mitigate DOX-induced cardiotoxicity is under investigation.

Purpose of the Study:

• To test if low-intensity aerobic exercise combined with DOX treatment can offset DOX-induced cardiotoxicity.
• To determine if exercise improves the anti-tumor efficacy of DOX.
• To investigate the effects of concomitant exercise and DOX on cardiac function and tumor progression in a murine model.

Main Methods:

• A murine model of melanoma (B16F10) was used.
• Mice received either vehicle or doxorubicin (DOX) and were either sedentary or exercised on a treadmill.
• Cardiac function, tumor volume, body weight, and heart weight were assessed.

Main Results:

• Exercise combined with DOX treatment resulted in the lowest tumor volume.
• DOX treatment led to reduced body weight gain, smaller heart weights, and shorter tibial lengths.
• Exercise did not reverse DOX-induced cardiotoxic effects, including cardiac fibrosis and reduced stroke volume.

Conclusions:

• Exercise enhances the efficacy of doxorubicin in inhibiting melanoma tumor growth.
• Concomitant exercise does not mitigate subclinical doxorubicin-induced cardiotoxicity in this murine model.
• Further research is needed to explore strategies for preventing DOX-related cardiotoxicity during cancer treatment.